Saint Bernards Healthcare, Jonesboro, AR, USA.
Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5525-5528. doi: 10.26355/eurrev_202109_26664.
The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine is the first novel nucleoside-modified messenger ribonucleic acid (modRNA) vaccine to receive Emergency Use Authorization from the Food and Drug Administration in the United States. It is indicated to be used in patients ≥12 years-of-age as of May 25th, 2021, including populations with high atherosclerotic cardiovascular disease (ASCVD) burden. However, little is known about the potential impact this vaccine may have on serum lipoprotein levels in patients with familial hypercholesteremia (FH), who are predisposed to high ASCVD burden due to elevated low-density lipoprotein cholesterol (LDL-C). We present an interesting case where a patient with heterozygous FH (HeFH) and elevated triglycerides (TG)-controlled for years on medication and apheresis-experienced significantly elevated TG, one day after receiving his second Pfizer-BioNTech COVID-19 vaccine dose. It is not known whether this adverse event may be seen in other FH patients and may be worth assessing in such patients to determine the possibility of a rare adverse reaction from a COVID-19 vaccine.
辉瑞-生物科技公司的 2019 年冠状病毒病（COVID-19）疫苗是首款获得美国食品和药物管理局紧急使用授权的新型核苷修饰信使核糖核酸（modRNA）疫苗。截至 2021 年 5 月 25 日，该疫苗被批准用于 12 岁及以上的患者，包括高动脉粥样硬化性心血管疾病（ASCVD）负担人群。然而，对于家族性高胆固醇血症（FH）患者，即由于低密度脂蛋白胆固醇（LDL-C）升高而易患 ASCVD 高负担的人群，这种疫苗对血清脂蛋白水平可能产生的潜在影响知之甚少。我们呈现了一个有趣的病例，一名杂合子 FH（HeFH）患者，多年来通过药物和血浆置换治疗控制了甘油三酯（TG）水平，在接受第二剂辉瑞-生物科技公司的 COVID-19 疫苗后一天，其 TG 水平显著升高。目前尚不清楚这种不良事件是否会出现在其他 FH 患者中，值得在这些患者中进行评估，以确定 COVID-19 疫苗是否会引起罕见的不良反应。
